A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke
- PMID: 34758251
- DOI: 10.1056/NEJMoa2107727
A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke
Abstract
Background: The value of administering intravenous alteplase before endovascular treatment (EVT) for acute ischemic stroke has not been studied extensively, particularly in non-Asian populations.
Methods: We performed an open-label, multicenter, randomized trial in Europe involving patients with stroke who presented directly to a hospital that was capable of providing EVT and who were eligible for intravenous alteplase and EVT. Patients were randomly assigned in a 1:1 ratio to receive EVT alone or intravenous alteplase followed by EVT (the standard of care). The primary end point was functional outcome on the modified Rankin scale (range, 0 [no disability] to 6 [death]) at 90 days. We assessed the superiority of EVT alone over alteplase plus EVT, as well as noninferiority by a margin of 0.8 for the lower boundary of the 95% confidence interval for the odds ratio of the two trial groups. Death from any cause and symptomatic intracerebral hemorrhage were the main safety end points.
Results: The analysis included 539 patients. The median score on the modified Rankin scale at 90 days was 3 (interquartile range, 2 to 5) with EVT alone and 2 (interquartile range, 2 to 5) with alteplase plus EVT. The adjusted common odds ratio was 0.84 (95% confidence interval [CI], 0.62 to 1.15; P = 0.28), which showed neither superiority nor noninferiority of EVT alone. Mortality was 20.5% with EVT alone and 15.8% with alteplase plus EVT (adjusted odds ratio, 1.39; 95% CI, 0.84 to 2.30). Symptomatic intracerebral hemorrhage occurred in 5.9% and 5.3% of the patients in the respective groups (adjusted odds ratio, 1.30; 95% CI, 0.60 to 2.81).
Conclusions: In a randomized trial involving European patients, EVT alone was neither superior nor noninferior to intravenous alteplase followed by EVT with regard to disability outcome at 90 days after stroke. The incidence of symptomatic intracerebral hemorrhage was similar in the two groups. (Funded by the Collaboration for New Treatments of Acute Stroke consortium and others; MR CLEAN-NO IV ISRCTN number, ISRCTN80619088.).
Copyright © 2021 Massachusetts Medical Society.
Comment in
-
Trial of Intravenous Alteplase before Endovascular Treatment for Stroke.N Engl J Med. 2022 Feb 3;386(5):496. doi: 10.1056/NEJMc2119227. N Engl J Med. 2022. PMID: 35108478 No abstract available.
-
In acute ischemic stroke, EVT alone vs. IV alteplase plus EVT did not differ for functional outcome at 90 d.Ann Intern Med. 2022 Apr;175(4):JC42. doi: 10.7326/J22-0016. Epub 2022 Apr 5. Ann Intern Med. 2022. PMID: 35377718
Similar articles
-
Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke: The SKIP Randomized Clinical Trial.JAMA. 2021 Jan 19;325(3):244-253. doi: 10.1001/jama.2020.23522. JAMA. 2021. PMID: 33464334 Free PMC article. Clinical Trial.
-
Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.JAMA. 2021 Jan 19;325(3):234-243. doi: 10.1001/jama.2020.23523. JAMA. 2021. PMID: 33464335 Free PMC article. Clinical Trial.
-
Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.N Engl J Med. 2020 May 21;382(21):1981-1993. doi: 10.1056/NEJMoa2001123. Epub 2020 May 6. N Engl J Med. 2020. PMID: 32374959 Clinical Trial.
-
Efficacy and safety of endovascular treatment with or without intravenous alteplase in acute anterior circulation large vessel occlusion stroke: a meta-analysis of randomized controlled trials.Neurol Sci. 2022 Jun;43(6):3551-3563. doi: 10.1007/s10072-022-06017-8. Epub 2022 Mar 22. Neurol Sci. 2022. PMID: 35314911 Review.
-
Endovascular Thrombectomy Alone versus Combined with Intravenous Thrombolysis.World Neurosurg. 2017 Dec;108:850-858.e2. doi: 10.1016/j.wneu.2017.08.040. Epub 2017 Aug 18. World Neurosurg. 2017. PMID: 28823660 Review.
Cited by
-
Bridging the Gap: Improving Acute Ischemic Stroke Outcomes with Intravenous Thrombolysis Prior to Mechanical Thrombectomy.Neurol Int. 2024 Oct 22;16(6):1189-1202. doi: 10.3390/neurolint16060090. Neurol Int. 2024. PMID: 39449506 Free PMC article.
-
Safety and efficacy of bridging intravenous thrombolysis plus mechanical thrombectomy versus direct mechanical thrombectomy in different age groups of acute ischemic stroke patients.Acta Neurol Belg. 2024 Oct 22. doi: 10.1007/s13760-024-02672-0. Online ahead of print. Acta Neurol Belg. 2024. PMID: 39436555
-
The effect of intravenous thrombolysis in stroke patients with unsuccessful thrombectomy.Interv Neuroradiol. 2024 Sep 12:15910199241279009. doi: 10.1177/15910199241279009. Online ahead of print. Interv Neuroradiol. 2024. PMID: 39262342 Free PMC article.
-
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP.Mol Ther. 2024 Oct 2;32(10):3346-3355. doi: 10.1016/j.ymthe.2024.08.024. Epub 2024 Aug 26. Mol Ther. 2024. PMID: 39192584 Free PMC article.
-
Treatment outcome of bridge mechanical thrombectomy with different IV-tPA dosages in the standard and extended time window in real-world practice.Neuroradiol J. 2024 Aug 26:19714009241269447. doi: 10.1177/19714009241269447. Online ahead of print. Neuroradiol J. 2024. PMID: 39185692 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical